Yehud, Israel, September 14, 2009 --- BioControl Medical presentated today an analysis of heart rate variability data from the European pilot study of CardioFit for Congestive Heart Failure. The results were presented at the HFSA meeting in Boston.

The presentation was made by Robert Dennert of the Department of Cardiology, University Hospital, Maastricht , The Netherlands, and authored by the investigators of the European pilot study. Analysis of data obtained from the subjects who reached the 6-month follow-up visit showed significant decrease of the mean resting heart rate and increase of the mean pNN50 time domain component of HRV (68% improvement) following vagal stimulation therapy. The improvement in HRV was consistent with statistically and clinically significant improvements in quality of life (MLwHF®), 6-minute walk test, LV ejection fraction and IL-6, as well as with the favorable trend in left ventricular volumes and NT-ProBNP. The reduction at 6-months in NT-ProBNP was correlated (p<0.05) with the increase in pNN50 (multivariate analysis).

"The correlation between improvement in HRV and improvement in NT-ProBNP provides an insight into the mechanism of action of Vagus nerve stimulation for heart failure. HRV is known to be affected by vagal tone, which is depressed in patients with chronic heart failure and increased by such stimulation." said Dr. Dennert.

About BioControl Medical

BioControl develops and markets advanced implantable devices for the treatment of autonomic disorders, conditions whereby the autonomic nervous system ceases to function properly, resulting in a disruption to the control of involuntary body processes. The devices enable controlled electrical stimulation of various nerves to achieve therapeutic results. For more information please contact: info@biocontrol-medical.com.